Showing results (221-230 of 277) with videos related to
Sort By:
Pageof 28
The New England Journal of Medicine|March 30, 2012
Brodalumab, an anti-interleukin-17-receptor antibody for psoriasisKim A Papp, Craig Leonardi, Alan Menter, et al.Journal of the American Academy of Dermatology|January 30, 2013
OBSERVE-5 interim analysis: an observational postmarketing safety registry of etanercept for the treatment of psoriasisAlexa B Kimball, David Pariser, Paul S Yamauchi, et al.The Journal of Pharmacology and Experimental Therapeutics|June 2, 2012
Intestinal transport of aminopterin enantiomers in dogs and humans with psoriasis is stereoselective: evidence for a mechanism involving the proton-coupled folate transporterAlan Menter, Breck Thrash, Christina Cherian, et al.Dermatitis : Contact, Atopic, Occupational, Drug|December 17, 2020
High Levels of Psychological Distress, Sleep Disturbance, and Alcohol Use Disorder in Adults With Atopic DermatitisEimear Gilhooley, Ciara O'Grady, Darren Roche, et al.Dermatology and Therapy|October 28, 2017
Patients' Perspectives on the Impact of Genital Psoriasis: A Qualitative StudyJennifer Clay Cather, Caitriona Ryan, Kim Meeuwis, et al.Bjpsych Open|February 1, 2024
Psychotropic medicines' prevalence, patterns and effects on cognitive and physical function in older adults with intellectual disability in Ireland: longitudinal cohort study, 2009-2020Marina Odalović, Ashleigh Gorman, Aviejay Paul, et al.Journal of the American Academy of Dermatology|October 3, 2006
Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension studyKenneth B Gordon, Richard G Langley, Craig Leonardi, et al.Journal of the American Academy of Dermatology|August 12, 2015
Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS studyIan Landells, Colleen Marano, Ming-Chun Hsu, et al.The Journal of Allergy and Clinical Immunology|March 15, 2015
Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trialJames G Krueger, Laura K Ferris, Alan Menter, et al.Cutis|November 6, 2010
Optimizing topical therapies for treating psoriasis: a consensus conferenceJoshua A Zeichner, Mark G Lebwohl, Alan Menter, et al.Pageof 28